A Simplified Derivative of Human Defensin 5 with Potent and Efficient Activity against Multidrug-Resistant Acinetobacter baumannii

Antimicrob Agents Chemother. 2018 Jan 25;62(2):e01504-17. doi: 10.1128/AAC.01504-17. Print 2018 Feb.

Abstract

The increasing incidence of multidrug-resistant Acinetobacter baumannii (MDRAb) infections worldwide has necessitated the development of novel antibiotics. Human defensin 5 (HD5) is an endogenous peptide with a complex architecture and antibacterial activity against MDRAb In the present study, we attempted to simplify the structure of HD5 by removing disulfide bonds. We found that the Cys2-4 bond was most indispensable for HD5 to inactivate MDRAb, although the antibacterial activity of the derivative was significantly attenuated. We then replaced the noncationic and nonhydrophobic residues with electropositive Arg to increase the antibacterial activity of HD5 derivative that contains a Cys2-4 bond, obtaining another derivative termed HD5d5. The in vitro antibacterial assay and irradiation-wound-infection animal experiment both showed that HD5d5 was much more effective than HD5 at eliminating MDRAb Further investigations revealed that HD5d5 efficiently bound to outer membrane lipid A and penetrated membranes, leading to bacterial collapse and peptide translocation. Compared to HD5, more HD5d5 molecules were located in the cytoplasm of MDRAb, and HD5d5 was more efficient at reducing the activities of superoxide dismutase and catalase, causing the accumulation of reactive oxygen species that are detrimental to microbes. In addition, HD5 failed to suppress the pathogenic outer membrane protein A of Acinetobacter baumannii (AbOmpA) at concentrations up to 50 μg/ml, whereas HD5d5 strongly bound to AbOmpA and exhibited a dramatic toxin-neutralizing ability, thus expanding the repertoire of drugs that is available to treat MDRAb infections.

Keywords: Acinetobacter baumannii; defensin; membrane penetration; outer membrane protein A; reactive oxygen species.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter Infections / drug therapy*
  • Acinetobacter Infections / microbiology
  • Acinetobacter Infections / mortality
  • Acinetobacter Infections / pathology
  • Acinetobacter baumannii / drug effects*
  • Acinetobacter baumannii / genetics
  • Acinetobacter baumannii / growth & development
  • Acinetobacter baumannii / metabolism
  • Animals
  • Anti-Bacterial Agents / chemical synthesis
  • Anti-Bacterial Agents / pharmacology*
  • Bacterial Outer Membrane Proteins / antagonists & inhibitors
  • Bacterial Outer Membrane Proteins / genetics
  • Bacterial Outer Membrane Proteins / metabolism
  • Bacterial Proteins / genetics
  • Bacterial Proteins / metabolism
  • Catalase / antagonists & inhibitors
  • Catalase / genetics
  • Catalase / metabolism
  • Disease Models, Animal
  • Dose-Response Relationship, Drug
  • Female
  • Gene Expression Regulation, Bacterial*
  • Humans
  • Lipid A / metabolism
  • Mice
  • Mice, Inbred BALB C
  • Protein Binding
  • Protein Engineering / methods
  • Protein Isoforms / chemical synthesis
  • Protein Isoforms / pharmacology
  • Protein Transport
  • Reactive Oxygen Species / agonists
  • Reactive Oxygen Species / metabolism
  • Superoxide Dismutase / antagonists & inhibitors
  • Superoxide Dismutase / genetics
  • Superoxide Dismutase / metabolism
  • Survival Analysis
  • Whole-Body Irradiation
  • Wound Infection / drug therapy*
  • Wound Infection / microbiology
  • Wound Infection / mortality
  • Wound Infection / pathology
  • alpha-Defensins / chemical synthesis
  • alpha-Defensins / pharmacology*

Substances

  • Anti-Bacterial Agents
  • Bacterial Outer Membrane Proteins
  • Bacterial Proteins
  • DEFA5 protein, human
  • Lipid A
  • Protein Isoforms
  • Reactive Oxygen Species
  • alpha-Defensins
  • OMPA outer membrane proteins
  • Catalase
  • Superoxide Dismutase